Pharmaceuticals News and Research

RSS

Elis granted exclusive rights to market Apricus Bio's Vitaros in the Gulf and part of the Middle East

Apricus Biosciences, Inc. and Elis Pharmaceuticals, announced today that the two companies have entered into a licensing agreement granting Elis the exclusive rights to market Apricus Bio's new drug for erectile dysfunction, Vitaros®, in the Gulf and part of the Middle East. "This new agreement is the next step in our strategy of seeking to partner Vitaros in more than 100 countries around the world," said Dr. Bassam Damaj, President and Chief Executive Officer of Apricus Bio.

5 Jan 2011

Dongsheng obtains exclusive sales rights of Thymosin Alpha 1 Injection in China

Dongsheng Pharmaceutical International Co., Ltd. announced today that it has obtained the exclusive sales rights of Thymosin Alpha 1 Injection in 19 provinces in China from Shanghai Biochemistry Pharmaceutical Co. I.

5 Jan 2011

Thomson Reuters and ChemAxon enter strategic partnership

The IP Solutions business of Thomson Reuters®, the leader in intellectual property research and analysis solutions, and ChemAxon, the leader in cheminformatics software for the life sciences industry, today announced a strategic partnership whereby Thomson Reuters is providing its chemical IP Data Feeds – Markush Structures and patent data to users of ChemAxon's JChem chemical software platform.

5 Jan 2011

Alnylam presents ALN-VSP Phase I trial results for liver cancer

Alnylam Pharmaceuticals, a leading RNAi therapeutics company, today presented new clinical data from its ALN-VSP Phase I liver cancer trial in a presentation at the Dana-Farber Cancer Institute in Boston. Results from molecular analysis of human biopsy samples showed achievement of pharmacologically relevant siRNA drug levels in tissues.

5 Jan 2011

Santaris Pharma, Pfizer expand RNA-targeted medicine collaboration

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, and Pfizer Inc., today announced that the companies have expanded their collaboration directed to the development and commercialization of RNA-targeted medicines using Santaris Pharma A/S Locked Nucleic Acid (LNA) Drug Platform.

5 Jan 2011

Footstar to acquire CPEX Pharmaceuticals

Footstar, Inc. announced today that certain of its subsidiaries have entered into a definitive merger agreement with CPEX Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, in a transaction valued at approximately $76.6 million, plus fees and expenses relating to the transaction.

5 Jan 2011

New wound care eLearning Portal for clinicians

Derma Sciences, a medical device and pharmaceutical company focused on advanced wound care, announces the launch of a new eLearning Portal to provide clinicians with valuable educational programs to ensure they are kept abreast of the latest information and product solutions in the Company's advanced wound care line.

5 Jan 2011

Kiadis Pharma, Hospira sign license agreement to develop and commercialize ATIR hematology product

Kiadis Pharma, a biopharmaceutical company based in The Netherlands, announced that it has entered into a licensing agreement with Hospira, Inc., a global specialty pharmaceutical company, to develop and commercialize Kiadis Pharma's ATIR™.

5 Jan 2011

VENENUM Biodesign relocates to new, state-of-the-art facility in Hamilton

VENENUM Biodesign, a drug discovery company that utilizes ultra-high throughput screening (UHTS) of its compound collection to identify hits against its novel disease-based targets or its partners' targets, announced today its relocation to a brand-new, state-of-the-art facility in Hamilton, NJ in Mercer County.

5 Jan 2011

Spectrum submits FUSILEV sNDA for treatment of colorectal cancer

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced it submitted a supplemental New Drug Application with the U.S. Food and Drug Administration (FDA) for a Ready-to-Use formulation of FUSILEV (levoleucovorin) for Injection.

5 Jan 2011

Opinions: U.S. International Affairs Budget; Health impacts of climate change; Role of U.N.; Drug development, free trade

Despite challenging economic times, "[t]wo areas we cannot afford to shortchange right now ... are our national security and our economic prosperity, which is why we must continue to have a strong and effective International Affairs Budget," U.S. Global Leadership Coalition Communications Director Richard Parker writes in a FoxNews.com opinion piece.

5 Jan 2011

Bioniche Life Sciences announces completion of Australian Offer and raises gross proceeds of A$12.5 million

Bioniche Life Sciences In., a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has successfully completed its Australian Offer of 8.6 million CHESS Depositary Instruments at A$1.45 per CDI, raising gross proceeds of A$12.5 million.

4 Jan 2011

Anadys begins ANA598 Phase IIb study for hepatitis C

Anadys Pharmaceuticals, Inc. announced today that it has initiated the planned Phase IIb study of ANA598 in combination with pegylated interferon and ribavirin. The protocol for the study has been cleared by the United States Food and Drug Administration and Health Canada.

4 Jan 2011

PanOptica completes $30 million Series A financing

PanOptica, Inc., a private biopharmaceutical company focused on licensing and developing innovative ophthalmology therapies, today announced that it has raised $30 million in a Series A financing. This round was led by SV Life Sciences and Third Rock Ventures.

4 Jan 2011

Isis commences ISIS-EIF4ERx Phase 2 studies in non-small cell lung cancer and prostate cancer

Isis Pharmaceuticals, Inc. announced the initiation of two Phase 2 studies of ISIS-EIF4ERx in patients with non-small cell lung cancer and prostate cancer. These studies are part of Isis' broad Phase 2 development program designed to evaluate ISIS-EIF4ERx in multiple types of cancer. ISIS-EIF4ERx targets eukaryotic initiation factor-4E (eIF-4E), a traditionally "undruggable" target that is thought to promote tumor growth and metastasis in many cancers.

4 Jan 2011

ddn conducts interview with lead plaintiff related to embryonic stem cell research case

Drug Discovery News, a news organization covering issues, trends and product news in the pharmaceutical drug development and discovery industry, recently conducted exclusive interviews with the lead plaintiffs in the controversial Sherley v. Sebelius lawsuit challenging President Barack Obama's order granting funding for embryonic stem cell research.

4 Jan 2011

New USP standards to improve health literacy, proper medication usage among patients

For the first time, universal standards to guide the content, language, format and appearance of prescription medication labels to reflect how patients read and understand medication instructions are being proposed on a national level.

4 Jan 2011

BNA announces publication of Second Edition of Pharmaceutical Patent Law

BNA Books, a division of BNA, announces the publication of the Second Edition of Pharmaceutical Patent Law, the most relied upon reference available with a detailed, practitioner-oriented treatment of pharmaceutical patent law from the perspective of both patent law and the food and drug laws.

4 Jan 2011

AHF to supply $1 million in free AIDS drugs to Florida's disenrolled and wait listed HIV/AIDS patients

As the State of Florida grapples with a budget shortfall that has crippled its AIDS Drug Assistance Program (ADAP) and forced the state to potentially disenroll 350 Florida patients already on ADAP as well as place nearly 2,400 low-income Floridians on waiting lists to access lifesaving medications, AIDS Healthcare Foundation (AHF) has proposed an innovative plan to help state health officials and displaced HIV/AIDS patients bridge the transition to private patient assistance programs run by the major pharmaceutical companies.

4 Jan 2011

MGH, Veridex establish research center of excellence on circulating tumor cell technologies

Massachusetts General Hospital (MGH) has entered into a collaborative agreement with Veridex LLC to establish a center of excellence in research on circulating tumor cell (CTC) technologies. The overall goal of the agreement is to develop and commercialize novel technologies for capturing and characterizing CTCs, solid tumor cells found at extremely low levels in the bloodstream, which may offer a key to noninvasive characterization of cancer and potentially to early detection.

4 Jan 2011

Pharmaceuticals News and Research

Elis granted exclusive rights to market Apricus Bio's Vitaros in the Gulf and part of the Middle East

Dongsheng obtains exclusive sales rights of Thymosin Alpha 1 Injection in China

Thomson Reuters and ChemAxon enter strategic partnership

Alnylam presents ALN-VSP Phase I trial results for liver cancer

Santaris Pharma, Pfizer expand RNA-targeted medicine collaboration

Footstar to acquire CPEX Pharmaceuticals

New wound care eLearning Portal for clinicians

Kiadis Pharma, Hospira sign license agreement to develop and commercialize ATIR hematology product

VENENUM Biodesign relocates to new, state-of-the-art facility in Hamilton

Spectrum submits FUSILEV sNDA for treatment of colorectal cancer

Opinions: U.S. International Affairs Budget; Health impacts of climate change; Role of U.N.; Drug development, free trade

Bioniche Life Sciences announces completion of Australian Offer and raises gross proceeds of A$12.5 million

Anadys begins ANA598 Phase IIb study for hepatitis C

PanOptica completes $30 million Series A financing

Isis commences ISIS-EIF4ERx Phase 2 studies in non-small cell lung cancer and prostate cancer

ddn conducts interview with lead plaintiff related to embryonic stem cell research case

New USP standards to improve health literacy, proper medication usage among patients

BNA announces publication of Second Edition of Pharmaceutical Patent Law

AHF to supply $1 million in free AIDS drugs to Florida's disenrolled and wait listed HIV/AIDS patients

MGH, Veridex establish research center of excellence on circulating tumor cell technologies

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence